BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 16140777)

  • 1. Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors.
    Goodfellow IG; Evans DJ; Blom AM; Kerrigan D; Miners JS; Morgan BP; Spiller OB
    J Virol; 2005 Sep; 79(18):12016-24. PubMed ID: 16140777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice.
    Yanagawa B; Spiller OB; Proctor DG; Choy J; Luo H; Zhang HM; Suarez A; Yang D; McManus BM
    J Infect Dis; 2004 Apr; 189(8):1431-9. PubMed ID: 15073680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction with coxsackievirus and adenovirus receptor, but not with decay-accelerating factor (DAF), induces A-particle formation in a DAF-binding coxsackievirus B3 isolate.
    Milstone AM; Petrella J; Sanchez MD; Mahmud M; Whitbeck JC; Bergelson JM
    J Virol; 2005 Jan; 79(1):655-60. PubMed ID: 15596863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor.
    Martino TA; Petric M; Brown M; Aitken K; Gauntt CJ; Richardson CD; Chow LH; Liu PP
    Virology; 1998 May; 244(2):302-14. PubMed ID: 9601501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of two coxsackievirus B3 strains: putative influence of virus-receptor interactions on pathogenesis.
    Selinka HC; Wolde A; Pasch A; Klingel K; Schnorr JJ; Küpper JH; Lindberg AM; Kandolf R
    J Med Virol; 2002 Jun; 67(2):224-33. PubMed ID: 11992583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virus receptor trap neutralizes coxsackievirus in experimental murine viral myocarditis.
    Lim BK; Choi JH; Nam JH; Gil CO; Shin JO; Yun SH; Kim DK; Jeon ES
    Cardiovasc Res; 2006 Aug; 71(3):517-26. PubMed ID: 16806133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of coxsackievirus B3 interaction with human, but not murine, decay-accelerating factor: replacement of a single residue within short consensus repeat 2 prevents virus attachment.
    Pan J; Zhang L; Organtini LJ; Hafenstein S; Bergelson JM
    J Virol; 2015 Jan; 89(2):1324-8. PubMed ID: 25392210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variations of coxsackievirus B3 capsid primary structure, ligands, and stability are selected for in a coxsackievirus and adenovirus receptor-limited environment.
    Carson SD; Chapman NM; Hafenstein S; Tracy S
    J Virol; 2011 Apr; 85(7):3306-14. PubMed ID: 21270163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievirus B3 PD infection.
    Zautner AE; Körner U; Henke A; Badorff C; Schmidtke M
    J Virol; 2003 Sep; 77(18):10071-7. PubMed ID: 12941917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coxsackie B viruses that use human DAF as a receptor infect pig cells via pig CAR and do not use pig DAF.
    Spiller OB; Goodfellow IG; Evans DJ; Hinchliffe SJ; Morgan BP
    J Gen Virol; 2002 Jan; 83(Pt 1):45-52. PubMed ID: 11752699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells.
    Shafren DR; Williams DT; Barry RD
    J Virol; 1997 Dec; 71(12):9844-8. PubMed ID: 9371658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of coxsackievirus-B3-infected BALB/c mice with the soluble coxsackie adenovirus receptor CAR4/7 aggravates cardiac injury.
    Dörner A; Grunert HP; Lindig V; Chandrasekharan K; Fechner H; Knowlton KU; Isik A; Pauschinger M; Zeichhardt H; Schultheiss HP
    J Mol Med (Berl); 2006 Oct; 84(10):842-51. PubMed ID: 16924471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More recent swine vesicular disease virus isolates retain binding to coxsackie-adenovirus receptor, but have lost the ability to bind human decay-accelerating factor (CD55).
    Jimenez-Clavero MA; Escribano-Romero E; Ley V; Spiller OB
    J Gen Virol; 2005 May; 86(Pt 5):1369-1377. PubMed ID: 15831949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of decay-accelerating factor with coxsackievirus B3.
    Hafenstein S; Bowman VD; Chipman PR; Bator Kelly CM; Lin F; Medof ME; Rossmann MG
    J Virol; 2007 Dec; 81(23):12927-35. PubMed ID: 17804498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-dependent enhancement of coxsackievirus B3 infection of primary CD19+ B lymphocytes.
    Jarasch-Althof N; Wiesener N; Schmidtke M; Wutzler P; Henke A
    Viral Immunol; 2010 Aug; 23(4):369-76. PubMed ID: 20712481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decay-accelerating factor (CD55) promotes CD1d expression and Vgamma4+ T-cell activation in coxsackievirus B3-induced myocarditis.
    Huber S; Song WC; Sartini D
    Viral Immunol; 2006; 19(2):156-66. PubMed ID: 16817758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-Point Mutations within the Coxsackie B Virus Receptor-Binding Site Promote Resistance against Soluble Virus Receptor Traps.
    Pinkert S; Kopp A; Brückner V; Fechner H; Beling A
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Treatment of Coxsackievirus B3-Infected Animals With Soluble Coxsackievirus-Adenovirus Receptor Inhibits Development of Chronic Coxsackievirus B3 Cardiomyopathy.
    Pinkert S; Dieringer B; Klopfleisch R; Savvatis K; Van Linthout S; Pryshliak M; Tschöpe C; Klingel K; Kurreck J; Beling A; Fechner H
    Circ Heart Fail; 2019 Nov; 12(11):e005250. PubMed ID: 31718319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The coxsackie-adenovirus receptor (CAR) is used by reference strains and clinical isolates representing all six serotypes of coxsackievirus group B and by swine vesicular disease virus.
    Martino TA; Petric M; Weingartl H; Bergelson JM; Opavsky MA; Richardson CD; Modlin JF; Finberg RW; Kain KC; Willis N; Gauntt CJ; Liu PP
    Virology; 2000 May; 271(1):99-108. PubMed ID: 10814575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus-receptor interactions of coxsackie B viruses and their putative influence on cardiotropism.
    Selinka HC; Wolde A; Sauter M; Kandolf R; Klingel K
    Med Microbiol Immunol; 2004 May; 193(2-3):127-31. PubMed ID: 12920584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.